Immuno-Oncology-Global Market Status & Trend Report 2016-2026 Top 20 Countries Data
Report Summary
Immuno-Oncology-Global Market Status & Trend Report 2016-2026 Top 20 Countries Data offers a comprehensive analysis on Immuno-Oncology industry, standing on the readers’ perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Top 20 Countries Market Size of Immuno-Oncology 2016-2021, and development forecast 2022-2026
Main manufacturers/suppliers of Immuno-Oncology worldwide and market share by regions, with company and product introduction, position in the Immuno-Oncology market
Market status and development trend of Immuno-Oncology by types and applications
Cost and profit status of Immuno-Oncology, and marketing status
Market growth drivers and challengesSince the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency.The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Ammonium Immuno-Oncology market in 2020.COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.This report also analyses the impact of Coronavirus COVID-19 on the Immuno-Oncology industry.
The report segments the global Immuno-Oncology market as:
Global Immuno-Oncology Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2016-2026):
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)
Asia Pacific (China, Japan, India, Southeast Asia and Australia)
Latin America (Brazil, Argentina and Colombia)
Middle East and Africa
Global Immuno-Oncology Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2016-2026):
Immune Checkpoint Inhibitors
Cytokine-Based Immunotherapy
Cancer Vaccines
CAR-T Cell Therapy
Others
Global Immuno-Oncology Market: Application Segment Analysis (Consumption Volume and Market Share 206-2026; Downstream Customers and Market Analysis)
Hospitals
Drugstores
Others
Global Immuno-Oncology Market: Manufacturers Segment Analysis (Company and Product introduction, Immuno-Oncology Sales Volume, Revenue, Price and Gross Margin):
Bristol-Myers Squibb
Merck & Co., Inc.
Roche AG
AstraZeneca, Plc
Sanofi S.A.
Dendreon Pharmaceuticals
Novartis
Gilead Sciences Inc.
Merck KGaA
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Immuno-Oncology-Global Market Status & Trend Report 2016-2026 Top 20 Countries Data offers a comprehensive analysis on Immuno-Oncology industry, standing on the readers’ perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Top 20 Countries Market Size of Immuno-Oncology 2016-2021, and development forecast 2022-2026
Main manufacturers/suppliers of Immuno-Oncology worldwide and market share by regions, with company and product introduction, position in the Immuno-Oncology market
Market status and development trend of Immuno-Oncology by types and applications
Cost and profit status of Immuno-Oncology, and marketing status
Market growth drivers and challengesSince the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency.The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Ammonium Immuno-Oncology market in 2020.COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.This report also analyses the impact of Coronavirus COVID-19 on the Immuno-Oncology industry.
The report segments the global Immuno-Oncology market as:
Global Immuno-Oncology Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2016-2026):
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)
Asia Pacific (China, Japan, India, Southeast Asia and Australia)
Latin America (Brazil, Argentina and Colombia)
Middle East and Africa
Global Immuno-Oncology Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2016-2026):
Immune Checkpoint Inhibitors
Cytokine-Based Immunotherapy
Cancer Vaccines
CAR-T Cell Therapy
Others
Global Immuno-Oncology Market: Application Segment Analysis (Consumption Volume and Market Share 206-2026; Downstream Customers and Market Analysis)
Hospitals
Drugstores
Others
Global Immuno-Oncology Market: Manufacturers Segment Analysis (Company and Product introduction, Immuno-Oncology Sales Volume, Revenue, Price and Gross Margin):
Bristol-Myers Squibb
Merck & Co., Inc.
Roche AG
AstraZeneca, Plc
Sanofi S.A.
Dendreon Pharmaceuticals
Novartis
Gilead Sciences Inc.
Merck KGaA
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF IMMUNO-ONCOLOGY
1.1 Definition of Immuno-Oncology in This Report
1.2 Commercial Types of Immuno-Oncology
1.2.1 Immune Checkpoint Inhibitors
1.2.2 Cytokine-Based Immunotherapy
1.2.3 Cancer Vaccines
1.2.4 CAR-T Cell Therapy
1.2.5 Others
1.3 Downstream Application of Immuno-Oncology
1.3.1 Hospitals
1.3.2 Drugstores
1.3.3 Others
1.4 Development History of Immuno-Oncology
1.5 Market Status and Trend of Immuno-Oncology 2016-2026
1.5.1 Global Immuno-Oncology Market Status and Trend 2016-2026
1.5.2 Regional Immuno-Oncology Market Status and Trend 2016-2026
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Immuno-Oncology 2016-2021
2.2 Sales Market of Immuno-Oncology by Regions
2.2.1 Sales Volume of Immuno-Oncology by Regions
2.2.2 Sales Value of Immuno-Oncology by Regions
2.3 Production Market of Immuno-Oncology by Regions
2.4 Global Market Forecast of Immuno-Oncology 2022-2026
2.4.1 Global Market Forecast of Immuno-Oncology 2022-2026
2.4.2 Market Forecast of Immuno-Oncology by Regions 2022-2026
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Immuno-Oncology by Types
3.2 Sales Value of Immuno-Oncology by Types
3.3 Market Forecast of Immuno-Oncology by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Immuno-Oncology by Downstream Industry
4.2 Global Market Forecast of Immuno-Oncology by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Immuno-Oncology Market Status by Countries
5.1.1 North America Immuno-Oncology Sales by Countries (2016-2021)
5.1.2 North America Immuno-Oncology Revenue by Countries (2016-2021)
5.1.3 United States Immuno-Oncology Market Status (2016-2021)
5.1.4 Canada Immuno-Oncology Market Status (2016-2021)
5.1.5 Mexico Immuno-Oncology Market Status (2016-2021)
5.2 North America Immuno-Oncology Market Status by Manufacturers
5.3 North America Immuno-Oncology Market Status by Type (2016-2021)
5.3.1 North America Immuno-Oncology Sales by Type (2016-2021)
5.3.2 North America Immuno-Oncology Revenue by Type (2016-2021)
5.4 North America Immuno-Oncology Market Status by Downstream Industry (2016-2021)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Immuno-Oncology Market Status by Countries
6.1.1 Europe Immuno-Oncology Sales by Countries (2016-2021)
6.1.2 Europe Immuno-Oncology Revenue by Countries (2016-2021)
6.1.3 Germany Immuno-Oncology Market Status (2016-2021)
6.1.4 UK Immuno-Oncology Market Status (2016-2021)
6.1.5 France Immuno-Oncology Market Status (2016-2021)
6.1.6 Italy Immuno-Oncology Market Status (2016-2021)
6.1.7 Russia Immuno-Oncology Market Status (2016-2021)
6.1.8 Spain Immuno-Oncology Market Status (2016-2021)
6.1.9 Benelux Immuno-Oncology Market Status (2016-2021)
6.2 Europe Immuno-Oncology Market Status by Manufacturers
6.3 Europe Immuno-Oncology Market Status by Type (2016-2021)
6.3.1 Europe Immuno-Oncology Sales by Type (2016-2021)
6.3.2 Europe Immuno-Oncology Revenue by Type (2016-2021)
6.4 Europe Immuno-Oncology Market Status by Downstream Industry (2016-2021)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Immuno-Oncology Market Status by Countries
7.1.1 Asia Pacific Immuno-Oncology Sales by Countries (2016-2021)
7.1.2 Asia Pacific Immuno-Oncology Revenue by Countries (2016-2021)
7.1.3 China Immuno-Oncology Market Status (2016-2021)
7.1.4 Japan Immuno-Oncology Market Status (2016-2021)
7.1.5 India Immuno-Oncology Market Status (2016-2021)
7.1.6 Southeast Asia Immuno-Oncology Market Status (2016-2021)
7.1.7 Australia Immuno-Oncology Market Status (2016-2021)
7.2 Asia Pacific Immuno-Oncology Market Status by Manufacturers
7.3 Asia Pacific Immuno-Oncology Market Status by Type (2016-2021)
7.3.1 Asia Pacific Immuno-Oncology Sales by Type (2016-2021)
7.3.2 Asia Pacific Immuno-Oncology Revenue by Type (2016-2021)
7.4 Asia Pacific Immuno-Oncology Market Status by Downstream Industry (2016-2021)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Immuno-Oncology Market Status by Countries
8.1.1 Latin America Immuno-Oncology Sales by Countries (2016-2021)
8.1.2 Latin America Immuno-Oncology Revenue by Countries (2016-2021)
8.1.3 Brazil Immuno-Oncology Market Status (2016-2021)
8.1.4 Argentina Immuno-Oncology Market Status (2016-2021)
8.1.5 Colombia Immuno-Oncology Market Status (2016-2021)
8.2 Latin America Immuno-Oncology Market Status by Manufacturers
8.3 Latin America Immuno-Oncology Market Status by Type (2016-2021)
8.3.1 Latin America Immuno-Oncology Sales by Type (2016-2021)
8.3.2 Latin America Immuno-Oncology Revenue by Type (2016-2021)
8.4 Latin America Immuno-Oncology Market Status by Downstream Industry (2016-2021)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Immuno-Oncology Market Status by Countries
9.1.1 Middle East and Africa Immuno-Oncology Sales by Countries (2016-2021)
9.1.2 Middle East and Africa Immuno-Oncology Revenue by Countries (2016-2021)
9.1.3 Middle East Immuno-Oncology Market Status (2016-2021)
9.1.4 Africa Immuno-Oncology Market Status (2016-2021)
9.2 Middle East and Africa Immuno-Oncology Market Status by Manufacturers
9.3 Middle East and Africa Immuno-Oncology Market Status by Type (2016-2021)
9.3.1 Middle East and Africa Immuno-Oncology Sales by Type (2016-2021)
9.3.2 Middle East and Africa Immuno-Oncology Revenue by Type (2016-2021)
9.4 Middle East and Africa Immuno-Oncology Market Status by Downstream Industry (2016-2021)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF IMMUNO-ONCOLOGY
10.1 Global Economy Situation and Trend Overview
10.2 Immuno-Oncology Downstream Industry Situation and Trend Overview
CHAPTER 11 IMMUNO-ONCOLOGY MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Immuno-Oncology by Major Manufacturers
11.2 Production Value of Immuno-Oncology by Major Manufacturers
11.3 Basic Information of Immuno-Oncology by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Immuno-Oncology Major Manufacturer
11.3.2 Employees and Revenue Level of Immuno-Oncology Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 IMMUNO-ONCOLOGY MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 Bristol-Myers Squibb
12.1.1 Company profile
12.1.2 Representative Immuno-Oncology Product
12.1.3 Immuno-Oncology Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb
12.2 Merck & Co., Inc.
12.2.1 Company profile
12.2.2 Representative Immuno-Oncology Product
12.2.3 Immuno-Oncology Sales, Revenue, Price and Gross Margin of Merck & Co., Inc.
12.3 Roche AG
12.3.1 Company profile
12.3.2 Representative Immuno-Oncology Product
12.3.3 Immuno-Oncology Sales, Revenue, Price and Gross Margin of Roche AG
12.4 AstraZeneca, Plc
12.4.1 Company profile
12.4.2 Representative Immuno-Oncology Product
12.4.3 Immuno-Oncology Sales, Revenue, Price and Gross Margin of AstraZeneca, Plc
12.5 Sanofi S.A.
12.5.1 Company profile
12.5.2 Representative Immuno-Oncology Product
12.5.3 Immuno-Oncology Sales, Revenue, Price and Gross Margin of Sanofi S.A.
12.6 Dendreon Pharmaceuticals
12.6.1 Company profile
12.6.2 Representative Immuno-Oncology Product
12.6.3 Immuno-Oncology Sales, Revenue, Price and Gross Margin of Dendreon Pharmaceuticals
12.7 Novartis
12.7.1 Company profile
12.7.2 Representative Immuno-Oncology Product
12.7.3 Immuno-Oncology Sales, Revenue, Price and Gross Margin of Novartis
12.8 Gilead Sciences Inc.
12.8.1 Company profile
12.8.2 Representative Immuno-Oncology Product
12.8.3 Immuno-Oncology Sales, Revenue, Price and Gross Margin of Gilead Sciences Inc.
12.9 Merck KGaA
12.9.1 Company profile
12.9.2 Representative Immuno-Oncology Product
12.9.3 Immuno-Oncology Sales, Revenue, Price and Gross Margin of Merck KGaA
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF IMMUNO-ONCOLOGY
13.1 Industry Chain of Immuno-Oncology
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF IMMUNO-ONCOLOGY
14.1 Cost Structure Analysis of Immuno-Oncology
14.2 Raw Materials Cost Analysis of Immuno-Oncology
14.3 Labor Cost Analysis of Immuno-Oncology
14.4 Manufacturing Expenses Analysis of Immuno-Oncology
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
1.1 Definition of Immuno-Oncology in This Report
1.2 Commercial Types of Immuno-Oncology
1.2.1 Immune Checkpoint Inhibitors
1.2.2 Cytokine-Based Immunotherapy
1.2.3 Cancer Vaccines
1.2.4 CAR-T Cell Therapy
1.2.5 Others
1.3 Downstream Application of Immuno-Oncology
1.3.1 Hospitals
1.3.2 Drugstores
1.3.3 Others
1.4 Development History of Immuno-Oncology
1.5 Market Status and Trend of Immuno-Oncology 2016-2026
1.5.1 Global Immuno-Oncology Market Status and Trend 2016-2026
1.5.2 Regional Immuno-Oncology Market Status and Trend 2016-2026
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Immuno-Oncology 2016-2021
2.2 Sales Market of Immuno-Oncology by Regions
2.2.1 Sales Volume of Immuno-Oncology by Regions
2.2.2 Sales Value of Immuno-Oncology by Regions
2.3 Production Market of Immuno-Oncology by Regions
2.4 Global Market Forecast of Immuno-Oncology 2022-2026
2.4.1 Global Market Forecast of Immuno-Oncology 2022-2026
2.4.2 Market Forecast of Immuno-Oncology by Regions 2022-2026
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Immuno-Oncology by Types
3.2 Sales Value of Immuno-Oncology by Types
3.3 Market Forecast of Immuno-Oncology by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Immuno-Oncology by Downstream Industry
4.2 Global Market Forecast of Immuno-Oncology by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Immuno-Oncology Market Status by Countries
5.1.1 North America Immuno-Oncology Sales by Countries (2016-2021)
5.1.2 North America Immuno-Oncology Revenue by Countries (2016-2021)
5.1.3 United States Immuno-Oncology Market Status (2016-2021)
5.1.4 Canada Immuno-Oncology Market Status (2016-2021)
5.1.5 Mexico Immuno-Oncology Market Status (2016-2021)
5.2 North America Immuno-Oncology Market Status by Manufacturers
5.3 North America Immuno-Oncology Market Status by Type (2016-2021)
5.3.1 North America Immuno-Oncology Sales by Type (2016-2021)
5.3.2 North America Immuno-Oncology Revenue by Type (2016-2021)
5.4 North America Immuno-Oncology Market Status by Downstream Industry (2016-2021)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Immuno-Oncology Market Status by Countries
6.1.1 Europe Immuno-Oncology Sales by Countries (2016-2021)
6.1.2 Europe Immuno-Oncology Revenue by Countries (2016-2021)
6.1.3 Germany Immuno-Oncology Market Status (2016-2021)
6.1.4 UK Immuno-Oncology Market Status (2016-2021)
6.1.5 France Immuno-Oncology Market Status (2016-2021)
6.1.6 Italy Immuno-Oncology Market Status (2016-2021)
6.1.7 Russia Immuno-Oncology Market Status (2016-2021)
6.1.8 Spain Immuno-Oncology Market Status (2016-2021)
6.1.9 Benelux Immuno-Oncology Market Status (2016-2021)
6.2 Europe Immuno-Oncology Market Status by Manufacturers
6.3 Europe Immuno-Oncology Market Status by Type (2016-2021)
6.3.1 Europe Immuno-Oncology Sales by Type (2016-2021)
6.3.2 Europe Immuno-Oncology Revenue by Type (2016-2021)
6.4 Europe Immuno-Oncology Market Status by Downstream Industry (2016-2021)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Immuno-Oncology Market Status by Countries
7.1.1 Asia Pacific Immuno-Oncology Sales by Countries (2016-2021)
7.1.2 Asia Pacific Immuno-Oncology Revenue by Countries (2016-2021)
7.1.3 China Immuno-Oncology Market Status (2016-2021)
7.1.4 Japan Immuno-Oncology Market Status (2016-2021)
7.1.5 India Immuno-Oncology Market Status (2016-2021)
7.1.6 Southeast Asia Immuno-Oncology Market Status (2016-2021)
7.1.7 Australia Immuno-Oncology Market Status (2016-2021)
7.2 Asia Pacific Immuno-Oncology Market Status by Manufacturers
7.3 Asia Pacific Immuno-Oncology Market Status by Type (2016-2021)
7.3.1 Asia Pacific Immuno-Oncology Sales by Type (2016-2021)
7.3.2 Asia Pacific Immuno-Oncology Revenue by Type (2016-2021)
7.4 Asia Pacific Immuno-Oncology Market Status by Downstream Industry (2016-2021)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Immuno-Oncology Market Status by Countries
8.1.1 Latin America Immuno-Oncology Sales by Countries (2016-2021)
8.1.2 Latin America Immuno-Oncology Revenue by Countries (2016-2021)
8.1.3 Brazil Immuno-Oncology Market Status (2016-2021)
8.1.4 Argentina Immuno-Oncology Market Status (2016-2021)
8.1.5 Colombia Immuno-Oncology Market Status (2016-2021)
8.2 Latin America Immuno-Oncology Market Status by Manufacturers
8.3 Latin America Immuno-Oncology Market Status by Type (2016-2021)
8.3.1 Latin America Immuno-Oncology Sales by Type (2016-2021)
8.3.2 Latin America Immuno-Oncology Revenue by Type (2016-2021)
8.4 Latin America Immuno-Oncology Market Status by Downstream Industry (2016-2021)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Immuno-Oncology Market Status by Countries
9.1.1 Middle East and Africa Immuno-Oncology Sales by Countries (2016-2021)
9.1.2 Middle East and Africa Immuno-Oncology Revenue by Countries (2016-2021)
9.1.3 Middle East Immuno-Oncology Market Status (2016-2021)
9.1.4 Africa Immuno-Oncology Market Status (2016-2021)
9.2 Middle East and Africa Immuno-Oncology Market Status by Manufacturers
9.3 Middle East and Africa Immuno-Oncology Market Status by Type (2016-2021)
9.3.1 Middle East and Africa Immuno-Oncology Sales by Type (2016-2021)
9.3.2 Middle East and Africa Immuno-Oncology Revenue by Type (2016-2021)
9.4 Middle East and Africa Immuno-Oncology Market Status by Downstream Industry (2016-2021)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF IMMUNO-ONCOLOGY
10.1 Global Economy Situation and Trend Overview
10.2 Immuno-Oncology Downstream Industry Situation and Trend Overview
CHAPTER 11 IMMUNO-ONCOLOGY MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Immuno-Oncology by Major Manufacturers
11.2 Production Value of Immuno-Oncology by Major Manufacturers
11.3 Basic Information of Immuno-Oncology by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Immuno-Oncology Major Manufacturer
11.3.2 Employees and Revenue Level of Immuno-Oncology Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 IMMUNO-ONCOLOGY MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 Bristol-Myers Squibb
12.1.1 Company profile
12.1.2 Representative Immuno-Oncology Product
12.1.3 Immuno-Oncology Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb
12.2 Merck & Co., Inc.
12.2.1 Company profile
12.2.2 Representative Immuno-Oncology Product
12.2.3 Immuno-Oncology Sales, Revenue, Price and Gross Margin of Merck & Co., Inc.
12.3 Roche AG
12.3.1 Company profile
12.3.2 Representative Immuno-Oncology Product
12.3.3 Immuno-Oncology Sales, Revenue, Price and Gross Margin of Roche AG
12.4 AstraZeneca, Plc
12.4.1 Company profile
12.4.2 Representative Immuno-Oncology Product
12.4.3 Immuno-Oncology Sales, Revenue, Price and Gross Margin of AstraZeneca, Plc
12.5 Sanofi S.A.
12.5.1 Company profile
12.5.2 Representative Immuno-Oncology Product
12.5.3 Immuno-Oncology Sales, Revenue, Price and Gross Margin of Sanofi S.A.
12.6 Dendreon Pharmaceuticals
12.6.1 Company profile
12.6.2 Representative Immuno-Oncology Product
12.6.3 Immuno-Oncology Sales, Revenue, Price and Gross Margin of Dendreon Pharmaceuticals
12.7 Novartis
12.7.1 Company profile
12.7.2 Representative Immuno-Oncology Product
12.7.3 Immuno-Oncology Sales, Revenue, Price and Gross Margin of Novartis
12.8 Gilead Sciences Inc.
12.8.1 Company profile
12.8.2 Representative Immuno-Oncology Product
12.8.3 Immuno-Oncology Sales, Revenue, Price and Gross Margin of Gilead Sciences Inc.
12.9 Merck KGaA
12.9.1 Company profile
12.9.2 Representative Immuno-Oncology Product
12.9.3 Immuno-Oncology Sales, Revenue, Price and Gross Margin of Merck KGaA
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF IMMUNO-ONCOLOGY
13.1 Industry Chain of Immuno-Oncology
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF IMMUNO-ONCOLOGY
14.1 Cost Structure Analysis of Immuno-Oncology
14.2 Raw Materials Cost Analysis of Immuno-Oncology
14.3 Labor Cost Analysis of Immuno-Oncology
14.4 Manufacturing Expenses Analysis of Immuno-Oncology
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
